dalpiciclib

Overview

Dalpiciclib (SHR6390) is an oral CDK4/6 (CDK4, CDK6) inhibitor that induces G1 cell cycle arrest and, in preclinical models, upregulates MHC class I expression and IFN signaling — providing rationale for combination with immune checkpoint inhibitors in immune-excluded tumors.

Evidence in the corpus

• Dalpiciclib + camrelizumab in anti-PD-1-refractory R/M NPC (NCT05724355, n=34): ORR 32.4%; median DOR 10.4 mo; median PFS 6.7 mo; grade ≥3 TRAE 76.5% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.